Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does CASIRIVIMAB\IMDEVIMAB Cause Hypotension? 211 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 211 reports of Hypotension have been filed in association with CASIRIVIMAB\IMDEVIMAB. This represents 5.0% of all adverse event reports for CASIRIVIMAB\IMDEVIMAB.

211
Reports of Hypotension with CASIRIVIMAB\IMDEVIMAB
5.0%
of all CASIRIVIMAB\IMDEVIMAB reports
7
Deaths
79
Hospitalizations

How Dangerous Is Hypotension From CASIRIVIMAB\IMDEVIMAB?

Of the 211 reports, 7 (3.3%) resulted in death, 79 (37.4%) required hospitalization, and 12 (5.7%) were considered life-threatening.

Is Hypotension Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for CASIRIVIMAB\IMDEVIMAB. However, 211 reports have been filed with the FAERS database.

What Other Side Effects Does CASIRIVIMAB\IMDEVIMAB Cause?

Infusion related reaction (875) Dyspnoea (687) Nausea (416) Oxygen saturation decreased (390) Dizziness (357) Pyrexia (306) Chest discomfort (294) Chills (265) Flushing (238) Cough (235)

What Other Drugs Cause Hypotension?

SACUBITRIL\VALSARTAN (11,718) AMLODIPINE (6,504) CALCIUM\DEXTROSE\MAGNESIUM\SODIUM\SODIUM (4,694) FUROSEMIDE (4,468) TREPROSTINIL (4,412) METOPROLOL (3,213) RITUXIMAB (3,208) METFORMIN (3,116) LENALIDOMIDE (2,920) ACETAMINOPHEN (2,817)

Which CASIRIVIMAB\IMDEVIMAB Alternatives Have Lower Hypotension Risk?

CASIRIVIMAB\IMDEVIMAB vs CASPOFUNGIN CASIRIVIMAB\IMDEVIMAB vs CATEQUENTINIB CASIRIVIMAB\IMDEVIMAB vs CC-4047 CASIRIVIMAB\IMDEVIMAB vs CEDAZURIDINE\DECITABINE CASIRIVIMAB\IMDEVIMAB vs CEDIRANIB

Related Pages

CASIRIVIMAB\IMDEVIMAB Full Profile All Hypotension Reports All Drugs Causing Hypotension CASIRIVIMAB\IMDEVIMAB Demographics